Katanosin B and plusbacin A3, inhibitors of peptidoglycan synthesis in methicillin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 6, 2001, Pages 1823-1827

  Maki, Hideki ^a   Miura, Kenji ^a   Yamano, Yoshinori ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; KATANOSIN B; PEPTIDOGLYCAN; PLUSBACIN A3; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; GLYCOSYLATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ACETYLGLUCOSAMINE; ANTI-BACTERIAL AGENTS; CELL WALL; CELLS, CULTURED; DEPSIPEPTIDES; ENTEROCOCCUS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; PEPTIDES; PEPTIDES, CYCLIC; PEPTIDOGLYCAN; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0034999983     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.6.1823-1827.2001     Document Type: Article

References (42)

1. Barna, J. C. J., and D. H. Williams. 1984. The structure and mode of action of glycopeptide antibiotics of the vancomycin group. Annu. Rev. Microbiol. 38:339-357.
2. Bonner, D. P., J. O'Sullivan, S. K. Tanaka, J. M. Clark, and R. R. Whitney. 1988. Lysobactin, a novel antibacterial agent produced by Lysobacter sp. II. Biological properties. J. Antibiot. 41:1745-1751.
3. Bouhss, A., D. Mengin-Lecreulx, D. L. Beller, and J. van Hijenoort. 1999. Topological analysis of the MraY protein catalysing the first membrane step of peptidoglycan synthesis. Mol. Microbiol. 34:576-585.
4. Brandish, P. E., M. K. Burnham, J. T. Lonsdale, R. Southgate, M. Inukai, and T. D. H. Bugg. 1996. Slow binding inhibition of phospho-N-acetylmuramyl-pentapeptide-translocase (Escherichia coli) by mureidomycin A. J. Biol. Chem. 271:7609-7614.
5. Brötz, H., M. Josten, I. Wiedemann, U. Schneider, F. Götz, G. Bierbaum, and H.-G. Sahl. 1998. Role of lipid-bound peptidoglycan precursors in the formation of pores by nisin, epidermin and other lantibiotics. Mol. Microbiol. 30:317-327.
6. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morb. Mortal. Wkly. Rep. 46:813-815.
7. Crouvoisier, M., D. Mengin-Lecreulx, and J. van Heijenoort. 1999. UDP-N-acetylglucosamine: N-acetylmuramoyl-(pentapetide) pyrophosphoryl undecaprenol N-acetylglucosamine transferase from Escherichia coli: overproduction, solubilization, and purification. FEBS Lett. 449:289-292.
8. Ha, S., E. Chang, M.-C. Lo, H. Men, P. Park, M. Ge, and S. Walker. 1999. The kinetic characterization of Escherichia coli MurG using synthetic substrate analogues. J. Am. Chem. Soc. 121:8415-8426.
9. Hanaki, H., K. Kuwahara-Arai, S. Boyle-Vavra, R. S. Daum, H. Labischinski, and K. Hiramatsu. 1998. Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50. J. Antimicrob. Chemother. 42:199-209.
10. Hanaki, H., H. Labischinski, Y. Inaba, N. Kondo, H. Murakami, and K. Hiramatsu. 1998. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J. Antimicrob. Chemother. 42:315-320.
11. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda, S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 350:1670-1673.
12. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguri, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-146.
13. Hunt, G. A., and A. J. Moses. 1958. Acute infection of mice with Smith strain of Staphylococcus aureus. Science 128:1574-1575.
14. Ikeda, M., M. Wachi, H. K. Jung, F. Ishino, and M. Matsuhashi. 1991. The Escherichia coli mraY gene encoding UDP-N-acetylmuramoyl-pentapeptide: undecaprenyl-phosphate phospho-N-acetylmuramoyl-pentapeptide transferase. J. Bacteriol. 173:1021-1026.
15. Ishino, F., and M. Matsuhashi. 1981. Peptidoglycan synthetic enzyme activities of highly purified penicillin-binding protein 3 in Escherichia coli: a septum-forming reaction sequence. Biochem. Biophys. Res. Commun. 101: 905-911.
16. Ishino, F., K. Mitsui, S. Tamaki, and M. Matsuhashi. 1980. Dual enzyme activities of cell wall peptidoglycan synthesis, peptidoglycan transglycosylase and penicillin-sensitive transpeptidase, in purified preparations of Escherichia coli penicillin-binding protein 1A. Biochem. Biophys. Res. Commun. 97:287-293.
17. Kato, T., H. Hinoo, Y. Terui, J. Kikuchi, and J. Shoji. 1988. The structures of katanosins A and B. J. Antibiot. 41:719-725.
18. Kopp, U., M. Roos, J. Wecke, and H. Labischinski. 1996. Staphylococcal peptidoglycan interpeptide bridge biosynthesis: a novel antistaphylococcal target? Microb. Drug Resist. 2:29-41.
19. Lugtenberg, E. J. J., and P. G. de Haan. 1971. A simple method for following the fate of alanine-containing components in murein synthesis in Escherichia coli. Antonie van Leeuwenhoek J. Microbiol. Serol. 37:537-552.
20. Matsuhashi, M., C. P. Dietrich, and J. L. Strominger. 1965. Incorporation of glycine into the cell wall glycopeptide in Staphylococcus aureus: role of sRNA and lipid intermediates. Proc. Natl. Acad. Sci. USA 54:587-594.
21. McDonald, L. C., M. J. Kuehnert, F. C. Tenover, and W. R. Jarvis. 1997. Vancomycin-resistant enterococci outside the health-care setting: prevalence, sources, and public health implications. Emerg. Infect. Dis. 3:311-317.
22. Men, H., P. Park, M. Ge, and S. Walker. 1998. Substrate synthesis and activity assay for MurG. J. Am. Chem. Soc. 120:2484-2485.
23. Mengin-Lecreulx, D., N. E. Allen, J. N. Hobbs, and J. van Haijenoort. 1990. Inhibition of peptidoglycan biosynthesis in Bacillus megaterium by daptomycin. FEMS Micobiol. Lett. 69:245-248.
24. Mengin-Lecreulx, D., L. Texier, M. Rousseau, and J. van Heijenoort. 1991. The murG gene of Escherichia coli codes for the UDP-N-acetylglucosamine: N-acetylmuramyl-(pentapeptide) pyrophosphoryl-undecaprenol N-acetylglucosamine transferase involved in the membrane steps of peptidoglycan synthesis. J. Bacteriol. 173:4625-4636.
25. Murakami, K., T. Fujimura, and M. Doi. 1994. Nucleotide sequence of the structural gene for the penicillin-binding protein 2 of Staphylococcus aureus and the presence of a homologous gene in other staphylococci. FEMS Microbiol. Lett. 117:131-136.
26. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
27. Nakagawa J., and M. Matsuhashi. 1982. Molecular divergence of a major peptidoglycan synthetase with transglycosylase-transpeptidase activities in Escherichia coli - penicillin-binding protein 1Bs. Biochem. Biophys. Res. Commun. 105:1546-1553.
28. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically - fourth edition; approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
29. Novick, R. 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33:155-166.
30. Park, W., and M. Matsuhashi. 1984. Staphylococcus aureus and Micrococcus luteus peptidoglycan transglycosylases that are not penicillin-binding proteins. J. Bacteriol. 157:538-544.
31. Pless, D. D., and F. C. Neuhaus. 1973. Initial membrane reaction in peptidoglycan synthesis. J. Biol. Chem. 248:1568-1576.
32. Reynolds, P. E. 1989. Structure, biochemistry and mechanism of action of glycopeptide antibiotics. Eur. J. Clin. Microbiol. Infect. Dis. 8:943-950.
33. Rohrer, S., K. Ehlert, M. Tschierske, H. Labischinski, and B. Berger-Bächi. 1999. The essential Staphylococcus aureus gene fmhB is involved in the first step of peptidoglycan pentaglycine interpeptide formation. Proc. Natl. Acad. Sci. USA 96:9351-9356.
34. Rotun, S. S., V. McMath, D. J. Schoonmaker, P. S. Maupin, F. C. Tenover, B. C. Hill, and D. M. Ackman. 1999. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteria. Emerg. Infect. Dis. 5:147-149.
35. Shoji, J., H. Hinoo, K. Matsumoto, T. Hattori, T. Yoshida, S. Matsuura, and E. Kondo. 1988. Isolation and characterization of katanosins A and B. J. Antibiot. 41:713-718.
36. Shoji, J., H. Hinoo, T. Katayama, K. Matsumoto, T. Tanimoto, T. Hattori, I. Higashiyama, H. Miwa, K. Motokawa, and T. Yoshida. 1992. Isolation and characterization of new peptide antibiotics, plusbacins A1 ∼ A4 and B1∼B4. J. Antibiot. 45:817-823.
37. Shoji, J., H. Hinoo, T. Katayama, Y. Nakagawa, Y. Ikenishi, K. Iwatani, and T. Yoshida. 1992. Structures of new peptide antibiotics, plusbacins A1∼A4 and B1∼B4. 45:824-831.
38. Sieradzki, K., R. B. Roberts, S. W. Haber, and A. Tomasz. 1999. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med. 340:517-523.
39. Smith, T. L., M. L. Pearson, K. R. Wilcox, C. Cruz, M. V. Lancaster, B. Robinson-Dunn, F. C. Tenover, M. J. Zervos, J. D. Band, E. White, and W. R. Jarvis. 1999. Emergence of vancomycin resistance in Staphylococcus aureus. N. Engl. J. Med. 340:493-501.
40. Somner, E. A., and P. E. Reynolds. 1990. Inhibition of peptidoglycan biosynthesis by ramoplanin. Antimicrob. Agents Chemother. 34:413-419.
41. Strominger, J. L., M. Matsuhashi, J. S. Anderson, C. P. Dietrich, P. M. Meadow, W. Katz, G. Siewert, and J. M. Gilbert. 1966. Glycopeptide synthesis in Staphylococcus aureus and Micrococcus lysodeikticus. Methods Enzymol. 8:473-486.
42. Tschierske, M., C. Mori, S. Rohrer, K. Ehlert, K. J. Shaw, and B. Berger-Bächi. 1999. Identification of three additional femAB-like open reading frames in Staphylococcus aureus. FEMS Microbiol. Lett. 171:97-102.